Business & Finance
DURECT Corporation reports 2019 financial results
4 March 2020 -

DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company, announced on Tuesday its financial results for the year ended 31 December 2019.

The company reported total revenues of USD29.6m in 2019 compared to total revenues of USD18.6m in 2018.

The firm posted net loss of USD20.6m or USD0.12 per share for 2019 compared to a net loss of USD25.3m or USD0.16 per share in 2018.

'The highlight of the year for DURECT in 2019 was achieving positive results from our DUR-928 Phase 2a alcoholic hepatitis (AH) study, which were featured in multiple presentations at the Liver Meeting 2019, including a late-breaking oral presentation by Dr Tarek Hassanein,' stated James E Brown, DVM, president and CEO of DURECT.